Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Decrease in Short Interest

Artelo Biosciences, Inc. (NASDAQ:ARTL) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 37,410 shares, a decline of 29.6% from the February 26th total of 53,146 shares. Currently, 6.0% of the company’s shares are sold short. Based on an average daily trading volume, of 40,491 shares, the days-to-cover ratio is currently 0.9 days.

Key Stories Impacting Artelo Biosciences

Here are the key news stories impacting Artelo Biosciences this week:

• Positive Sentiment: Announced a private placement to raise approximately $11.0 million in gross proceeds (3,188,407 shares and warrants), with warrants exercisable at $3.20 and potential additional proceeds if exercised — provides near-term cash for working capital and to repay bridge debt. Article Title
• Neutral Sentiment: Requested withdrawal of the recently effective S-1 registration statement — market reaction has been bullish but the company did not publicly frame the strategic reason; this may simply reflect a change in financing approach (private placement vs. registered offering). Article Title
• Neutral Sentiment: Multiple LULD (Limit Up/Limit Down) pauses and trading halts were recorded throughout the day — this is a mechanical response to sharp intraday moves and explains the repeated short interruptions in trading. (Internal Nasdaq halt records observed.)
• Negative Sentiment: The financing is priced well below recent trading levels and includes long-dated warrants, which could meaningfully dilute current shareholders if exercised; issuance under at-the-market rules and the exercise terms increase share count risk and investor uncertainty about long-term capital needs. Article Title

Artelo Biosciences Stock Up 230.4%

ARTL stock opened at $10.54 on Friday. The company has a market cap of $7.80 million, a price-to-earnings ratio of -0.17 and a beta of 1.04. The business has a fifty day simple moving average of $4.64 and a 200-day simple moving average of $7.27. Artelo Biosciences has a 52 week low of $2.95 and a 52 week high of $85.80.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Artelo Biosciences in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $54.00.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.